BRUCE POWER **FACTS**

Gamzook'aamin aakoziwin - Fighting cancer together

Bruce Power's site lies within the Traditional Treaty Territory of the Saugeen Ojibway Nation (SON). SON is comprised of two communities, the Chippewas of Nawash Unceded First Nation and the Chippewas of Saugeen First Nation. The SON people are Anishinaabek People of the Great Lakes Region.

SON describes both the Territory (lands and waters) and the People who have lived with and protected the Territory since time immemorial.

Bruce Power is committed to working toward true reconciliation and building partnerships that offer real and tangible benefits for Indigenous communities.

Bruce Power has partnered with SON in a historic collaboration to market medical isotopes. The partnership, named *Gamzook'aamin aakoziwin*, which translates to, "We are teaming up on the sickness," includes an equity stake for SON and a revenue-sharing program that provides a direct benefit to the community for the marketing of current and new isotopes produced through the new Isotope Production System.

Gamzook'aamin aakoziwin supports the global fight against cancer while creating new, meaningful economic opportunities within SON Territory. It demonstrates Bruce Power's recognition that the next 50 years of Bruce Power operation in SON Territory must be different than the past 50 years, as we move forward, fighting cancer together.

Gamzook'aamin aakoziwin
FIGHTING CANCER TOGETHER

LUTETIUM-177: AN HISTORIC COLLABORATION

Bruce Power and SON's first isotope collaboration is the production and marketing of lutetium-177, a short-lived medical isotope that is used in prostate cancer treatments. It is created in the first-of-a-kind Isotope Production System (IPS) installed in 2022 in Bruce Power's Unit 7.

Lutetium-177 produced at Bruce Power is used in precision oncology for targeted therapy of a growing number of cancers, including neuroendocrine tumours, and prostate and breast cancers. Lutetium-177-based treatments are designed to deploy precision nuclear medicine that precisely targets malignant cells while sparing surrounding healthy tissues.



SON-BRUCE POWER PARTNERSHIP: TIMELINE OF AN INNOVATION



CS230188 JULY2023 R000